Release Summary

Arrowhead presented clinical data from a Phase 2 study of ARC-520 and a Phase 1/2 study of ARC-521, against chronic hepatitis B infection, at The International Liver Congress™ 2017

Arrowhead Pharmaceuticals Inc.